Impact Factor
2.99
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.81
146 total citations
h5-index
20
h5 depth signal
Cited share
56.6%
30 of 53
Total citations
146
Citation footprint
Metric signal
2.53
External metric anchor
Self-citation
2.7%
4 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
174
United Kingdom
88
Germany
50
Canada
47
Italy
41
Citing Fields of Research
Neurodegenerative Disorders
318
Neuromuscular Disorders
153
Postural Control
33
Neurosciences
31
Nervous System Disorders
27
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
901
Articles tracked across the journal lifetime
Indexed publication set
53
30 cited publications
Last 12 months
91
7.6 publications/month
Open access share
17.6%
16 OA publications in the last year
Leading citing country
United States
174 citing publications
Leading citing field
Neurodegenerative Disorders
318 citing publications
Latest tracked publication
18 October 2026
10 recent records available
Coverage & Indexing History
v4n1, Feb. 2014-
v4n1, Feb. 2014- ; selected citations only before this date
Active Coverage
Research Focus & Classification
Indexed Subjects
Neurodegenerative Disorders
Broad Categories
Neurology
Neurodegenerative Disorders
Neuromuscular Disorders
MeSH Descriptors
Neurodegenerative Diseases
Outcome and Process Assessment, Health Care
Quality of Life
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1080/17582024.2026.2749397
Open DOI
Mapping care interventions for people living with motor neurone disease: a living evidence and gap map
02
DOI 10.1080/17582024.2026.2744191
Open DOI
Dual targeting of melatonergic and serotonergic neurotransmissions in Parkinson’s disease: role of agomelatine
03
04
DOI 10.1080/17582024.2026.2739332
Open DOI
Molecular and genetic basis of alzheimer’s disease and emerging treatment Modalities
05
DOI 10.1080/17582024.2026.2739337
Open DOI
Trends in mortality of Alzheimer’s disease with comorbid hypertension in patients in the US from 1999–2020
1. The world is experiencing a dramatic increase in the incidence of hypertension, with 1.3 billion adults affected globally and 115.3 million adults affected in the United States [1,2]. Alzheimer’...
06
DOI 10.1080/17582024.2026.2739334
Open DOI
Estrogen and progesterone receptor signaling as candidate neuroendocrine modulators in Huntington’s disease
1. Huntington’s disease (HD) is a monogenic neurodegenerative disorder caused by a CAG trinucleotide repeat expansion in the huntingtin (HTT) gene, leading to the production of mutant huntingtin (m...
07
08
DOI 10.1080/17582024.2026.2740131
Open DOI
Epidemiological associations between neurodegeneration and cancer – time to refine our research approach
Cancer and neurodegenerative diseases are devastating aging-related disorders. Epidemiological data suggest a general inverse risk association between them, the mechanisms of which might provide new avenues for developing treatments and ...
09
DOI 10.1080/17582024.2026.2731194
Open DOI
Plasma biomarker and machine learning modeling of clinical progression in cognitively normal individuals at risk for Alzheimer’s disease
1. Alzheimer’s disease (AD) continues to be one of the most pressing public health challenges globally. Over 55 million people presently have dementia, and this number is expected to nearly triple ...
10
DOI 10.1080/17582024.2026.2736021
Open DOI
Weak association of pathogenic ERBB4 variants with amyotrophic lateral sclerosis
1. The ErbB family of receptor tyrosine kinases comprises four members (ErbB1, ErbB2, ErbB3, ErbB4) and acts on epidermal growth factor and their derivatives, which regulate brain development and f...
Bibliographical & Catalog Notes
Also issued online.